U.S. Healthcare Services Stock News

Matador Resources (MTDR) is drawing attention after shifting expectations around its upcoming June 2026 quarter, with forecasts for higher earnings and revenue set against a recent downward revision to the consensus EPS estimate. See our latest analysis for Matador Resources. At a share price of $48.66, Matador Resources has seen a 12.22% year to date share price return. However, the 1 year total shareholder return is slightly negative at 2.08%, with the 3 year total shareholder return also...

In the second quarter ended June 30, 2026, KeyCorp reported net interest income of US$1,250 million and net income of US$509 million, up from US$1,141 million and US$425 million a year earlier, alongside net loan charge-offs rising to US$115 million from US$102 million. This combination of higher earnings per share and modestly higher credit losses points to stronger core profitability while risk costs inch higher. We’ll now examine how this earnings improvement, particularly the rise in net...

Astera Labs stock has delivered a 93.8% return over the past year. After that kind of move, the current valuation now looks closer to fair value, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model and market-based multiples both pointing to pricing that is about in line with fundamentals rather than clearly cheap. Over the last 12 months Astera Labs is up 93.8%, so the share price already reflects a lot of optimism about the company. Expectations for continued revenue...

RenaissanceRe Holdings Ltd. has reported past second-quarter 2026 results, with revenue of US$2,768.6 million and net income of US$663.08 million, alongside six-month diluted earnings per share from continuing operations of US$21.94 that exceeded the prior-year period. Over the same timeframe, the company also completed a substantial share repurchase program of 3,425,600 shares for US$995.69 million, returning a meaningful portion of capital to shareholders while shrinking its equity...

Earlier this week, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion backing Gilead Sciences’ Trodelvy in combination with Merck’s Keytruda as a first-line treatment for certain adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score of at least 10. This recommendation, grounded in Phase 3 ASCENT-04/KEYNOTE-D19 data showing a materially lower risk of...

NovoCure stock is coming off a very difficult five year stretch, with the share price down about 90%, yet the latest valuation checks still lean toward the shares looking cheap on several measures. That contrast, alongside fresh company developments in cancer therapies, is what investors are weighing now. Over the past five years, NovoCure shares have declined about 90%. As a result, any sign of a sustainable business recovery can have an outsized impact on how the market prices the...

Sales update puts fresh focus on Interparfums stock Interparfums (IPAR) has drawn fresh attention after reporting consolidated net sales of US$341 million for the second quarter and US$686 million for the first half of 2026, compared with the same periods a year earlier. See our latest analysis for Interparfums. Following the sales update, Interparfums shares trade at US$127.03, with a 30 day share price return of 15.51% and a year to date share price return of 48.68%. This points to strong...

US LNG exports are reshaping global gas flows, and that shift is starting to show up in individual stocks. As Louisiana grows into a major LNG hub and long term export contracts with Europe expand, some companies appear well placed for higher fee based volumes, while others face pressure from changing trade routes and pricing. This article walks through three stocks exposed to this news, with two that could benefit from the US export build out and one that may face headwinds, to help you...

OPKO Health (OPK) moved into focus after its Q2 2026 earnings report and guidance, which showed revenue of US$163.58 million and a sharply lower net loss compared with the prior year period. See our latest analysis for OPKO Health. OPKO Health shares have been volatile around the earnings release, with the 1-day share price return falling 17.27% after hitting a new 52-week high. However, the 90-day share price return of 24.09% and 1-year total shareholder return of 6.64% suggest momentum has...

Rogers stock slipped about 2% today, yet the quarter just reported looks more like a repair job gaining traction than a thesis breaking down. This is a company often treated as a high multiple materials pure play with a rich P/E and big expectations built into the story. The headline today is simple: profitability is rebuilding faster than the share price suggests, with Q2 basic earnings per share at roughly three times Q1 and revenue at about $216.8m. The gap between that improving income...

Earlier this week, IDEAYA Biosciences announced that it has begun Part 2 monotherapy expansion in its Phase 1/2 trial of IDE892, a highly selective PRMT5 inhibitor for MTAP-deleted solid tumors including non-small cell lung cancer and pancreatic ductal adenocarcinoma, at exposures expected to provide 24‑hour EC90 target coverage. An interesting element of this update is IDEAYA’s plan to position IDE892 as a combination backbone across MTAP-deleted cancers, including collaborations with...

Compañía de Minas BuenaventuraA (BVN) moved into focus after the company released detailed second quarter 2026 sales and production figures, alongside updated full year guidance for key metals output. See our latest analysis for Compañía de Minas BuenaventuraA. The updated production guidance landed against a mixed trading backdrop for Compañía de Minas BuenaventuraA, with the share price down 5.83% over the past week but up 5.70% year to date, while the 1 year and multi year total...

Sound Financial Bancorp stock barely flinched today, slipping just 0.5%, even though the quarter delivered a clear earnings jolt. Basic earnings per share for Q2 came in close to US$1, backed by revenue a little above US$11 million. For a small regional bank, that kind of profit engine can matter more than a fractional price move. The real story is margin power. Over the last twelve months, net profit margin moved into the high teens and earnings climbed sharply, yet the P/E sits at 14.1x...

nVent Electric (NYSE:NVT) reports a record US$2.6b order backlog tied to AI data center and infrastructure demand. Management updates revenue and EPS guidance along with plans for higher capital spending on new capacity. The scale and mix of the backlog provide added visibility into future project activity across key end markets. nVent Electric sits at the intersection of electrical connection, protection, and thermal management solutions that large infrastructure and data center projects...

Altria Group stock has delivered a strong 134.4% return over the past 5 years, and the latest intrinsic value checks using a Discounted Cash Flow (DCF) approach currently point to the shares trading at a discount of 43.7% to that estimate. Over 5 years Altria Group has returned 134.4%, which puts current valuation in focus after a solid period for long term holders. Recent FDA proposals that may tighten oversight of foreign tobacco manufacturers can support Altria Group's pricing power,...

Clean Harbors, Inc. has reported its second-quarter 2026 results, with sales of US$1,735.01 million and net income of US$170.46 million, alongside higher basic and diluted earnings per share from continuing operations compared with the same period in 2025. These stronger earnings figures, together with recently completed board leadership changes following founder Alan S. McKim’s retirement, highlight both improved profitability and an evolving governance framework for the environmental and...

Kinetik Holdings recently faced softer expectations for its June 2026 quarter, with analysts projecting a year-over-year decline in both earnings and revenue alongside a negative Earnings ESP. This shift in analyst estimates highlights mounting concern about near-term operational performance and how the company’s upcoming results may challenge prior assumptions. We’ll now examine how weaker expected quarterly earnings and a more cautious analyst stance could reshape Kinetik Holdings’ broader...

Why SL Green Realty’s latest quarter is drawing investor attention SL Green Realty (SLG) is back in focus after reporting second quarter 2026 funds from operations of $1.43 per share, ahead of expectations, alongside higher net rental revenue and better performance in its Manhattan portfolio. See our latest analysis for SL Green Realty. At a share price of US$53.82, SL Green Realty has seen a 26.9% 90 day share price return and a 14.61% year to date share price return, while the 3 year total...

Arbutus Biopharma and Genevant Sciences have launched new patent lawsuits targeting lipid nanoparticle technology used in Pfizer BioNTech (NasdaqGS:BNTX) COVID-19 vaccines. The actions seek monetary damages and potential injunctions across Canada and multiple European countries. See our latest analysis for BioNTech. For investors, the latest lawsuits arrive after a weaker period for BioNTech’s stock, with the share price at US$92.95 and short term momentum softening following a 90 day share...

Archer Aviation stock has fallen sharply over the past year, yet on simple market multiples it still screens as undervalued, leaving investors weighing weak recent returns against a mixed but not outright negative valuation picture. Archer Aviation shares are down 55.9% over the past year, which signals that sentiment around the stock has been under pressure even as news flow has been active. The new autonomous aircraft platforms with Anduril and the infrastructure push under the ACES...

Earlier this week, UDR, Inc. raised its full-year 2026 net income guidance to a range of US$1.03 to US$1.11 per diluted share, up from its prior US$0.91 to US$1.01 range, and projected third-quarter 2026 net income of US$0.13 to US$0.15 per diluted share. The guidance increase followed stronger-than-expected second-quarter performance, underpinned by solid occupancy, record resident retention, ongoing share repurchases, and new development activity amid a reshaping of its debt and asset...

In recent weeks, U.S. Bancorp completed a series of fixed‑income offerings totaling several billion US$, issued mainly as callable senior unsecured notes with fixed coupons ranging from 5.05% to 6.15% and fixed‑to‑floating structures maturing between 2030 and 2046. Alongside these bond sales, the bank reported higher second‑quarter net interest income and net income year over year, raised its 2026 revenue guidance, and continued share repurchases, underscoring management’s confidence while...

Procter & Gamble’s latest results have put fresh attention on how higher costs and softer volumes can affect even the largest consumer goods companies. Revenue came in at $21.2b, slightly below expectations, and management flagged a $1b after tax cost headwind and an estimated 8% drag on 2027 earnings guidance. For you as an investor, that kind of update can shift attention toward businesses that focus on private label and value products. This article looks at three stocks that appear exposed...

FirstEnergy stock slipped about 1% today, a muted reaction for a regulated utility that has been trading near the upper end of its recent range. The move understates the real tension in this quarter. The headline is not revenue or earnings per share; it is pressure on profitability at a time when investors already question how comfortably this balance sheet supports a premium P/E and a dividend that is not well covered by earnings. Q2 core earnings per share landed at about 50 cents and net...